AcroCyte Therapeutics

AcroCyte Therapeutics is a private biotechnology and life science tools company focused on scaffold-free 3D cell culture, organoid generation, and circulating tumor cell-enabled precision medicine. Its core R3CE platform is described by the company as a rapid, reproducible, rare-cell 3D expansion system that supports organoid and spheroid production from minimal patient samples for translational research, drug discovery, and personalized oncology applications. The company also highlights liquid biopsy and oncology assay capabilities, including CTC-based workflows, and has expanded into human-relevant model systems for New Approach Methodologies. In 2026, AcroCyte announced ARPA-H support to advance scalable human organoid technologies for regenerative medicine, indicating broader ambitions beyond oncology into tissue and organ regeneration. Overall, the company appears to operate primarily as a platform-driven biotech and research tools company rather than as a traditional therapeutics developer with a disclosed clinical drug pipeline.